The year that shaped the outcome of the OspA vaccine for human …
2022年1月27日 · The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes. PLoS One 12 , e0184357 (2017).
Safety and immunogenicity of a novel multivalent OspA-based …
2023年7月4日 · We investigated a novel Lyme borreliosis vaccine candidate (VLA15) targeting the six most common outer surface protein A (OspA) serotypes 1–6 to prevent infection with pathogenic Borrelia spp prevalent in Europe and North America.
The novel Lyme borreliosis vaccine VLA15 shows broad ... - PubMed
2017年9月1日 · We have previously shown that the Outer surface protein A (OspA) based Lyme borreliosis vaccine VLA15 induces protective immunity in mice. Herein, we report the induction of protective immunity by VLA15 with mouse models using ticks infected with B. burgdorferi (OspA serotype 1), B. afzelii (OspA se …
Optimisation of dose level and vaccination schedule for the VLA15 …
2024年5月31日 · We performed two studies in adults to optimise the dose level and vaccination schedule for VLA15, an investigational Lyme borreliosis vaccine targeting outer surface protein A (OspA) serotypes 1–6, which are associated with the most common pathogenic Borrelia species in Europe and North America.
Design and Development of a Novel Vaccine for Protection …
2014年11月19日 · In order to target all these pathogenic Borrelia species, we have designed a multivalent OspA-based vaccine. The vaccine includes three proteins, each containing the C-terminal half of two OspA serotypes linked to form a heterodimer.
The novel Lyme borreliosis vaccine VLA15 shows broad protection …
2017年9月1日 · Taken together, we could show that VLA15 induced protection in mice against challenge with four different clinically relevant Borrelia species (B. burgdorferi, B. afzelii, B. garinii and B. bavariensis) expressing five of the six OspA serotypes included in the vaccine.
VLA15, a new global Lyme disease vaccine undergoes clinical trials
2023年7月4日 · The VLA15 vaccine consists of three lipidated OspA heterodimers (reflecting six Borrelia OspA serotypes) expressed in Escherichia coli and formulated with an alum adjuvant. 5 This vaccine no longer contains the problematic epitope that was present in the LYMErix vaccine and which was thought to be associated with the development of autoimmune ...
Outer Surface Protein A - an overview | ScienceDirect Topics
Outer surface protein A (OspA) is a 31kDa immunogenic lipoprotein expressed on the surface of Borrelia burgdorferi, the causative agent of Lyme disease. From: Progress in Nuclear Magnetic Resonance Spectroscopy, 2013
Preclinical Evidence for the Protective Capacity of Antibodies …
2024年8月17日 · OspA is a validated vaccine target for the prevention of Lyme borreliosis caused by B burgdorferi, having proven protective in two prior clinical efficacy studies that assessed full-length native monovalent OspA ST1 Lyme disease vaccines among residents living in Lyme-endemic areas in the Northeastern United States [9, 10].
2024年1月23日 · 88 across the two or more of the OspA serotypes and use this information in the rational design of 89 novel vaccine antigens (32). With this goal in mind, we recently generated an epitope map of 90 OspA ST 1 using a collection of borreliacidal and transmission blocking human and …